Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 11Pancreatic Neoplasms 4Multiple Myeloma 4Urinary Bladder Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Mast-Cell 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2

Interventions

Irinotecan 15Gemcitabine 14Paclitaxel 13Cisplatin 13alvocidib 11Oxaliplatin 9Fluorouracil 9Taxes 7Leucovorin 7Carboplatin 7Bortezomib 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7tanespimycin 5Vorinostat 5Early Intervention, Educational 57-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine 4Topotecan 3Sorafenib 3Doxorubicin 3Docetaxel 3Capecitabine 3Bevacizumab 37-hydroxystaurosporine 3temsirolimus 2sargramostim 2ixabepilone 2eribulin 2aldesleukin 2VNP 20009 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Unspecified Adult Solid Tumor, Protocol Specific × Sunitinib × Clear all
NCT00357318 2014-02-24

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡